tRNAs are best known as basic modules for global regulation of protein synthesis. Goodarzi et al. now show that two tRNAs upregulated in metastatic breast cancer cells enhance stability and translation of transcripts enriched with these codons, leading to specific increase in production of prometastatic proteins.
While tRNAs are classically viewed as part of the basic machinery for protein synthesis, there has been debate about whether levels of tRNA expression contribute to specific phenotypes by regulating expression of a specific group of genes. Earlier work has shown that codon preference in an organism correlates with the abundance of the corresponding tRNA (Comeron, 2004) . Along this line, it has been proposed that tRNA pools in cells can be divided into subpopulations corresponding to those that support proliferation versus differentiation (Gingold et al., 2014) . In this issue of Cell, Goodarzi et al. (2016) show that two tRNAs are upregulated in metastatic breast cancer cell lines. These tRNAs enhance ribosome occupancy and translation efficiency of pro-metastatic genes enriched in their codons (Figure 1) . tRNAs are upregulated in breast cancer epithelial cells. Since tRNA modification and secondary structure make it difficult to generate reliable and consistent cDNA libraries of tRNAs for high-throughput sequencing, it has been challenging to identify the mechanistic and functional consequence of this phenomenon. Two recently published protocols employ bacterially encoded demethylase treatment before reverse transcription to improve the quality of cDNA library (Cozen et al., 2015; Zheng et al., 2015) Here, Goodarzi et al. (2016) developed a new approach to measure tRNA pool. They utilized specific pairs of DNA probes for each tRNA. The hybridized products were separated by a nick that could be ligated once the biotinylated tRNAs were pulled down on streptavidin beads. Libraries prepared from these splintligated probes are minimally amplified and sequenced. This allowed them to skip the reverse transcriptase step that is particularly be-devilled by tRNA modifications and secondary structure. Using this approach, they identified two tRNAs, tRNA Glu UUC in poorly metastatic cells enhanced their metastatic ability in lungs. Consistent with these findings, they showed that the levels of these tRNAs were higher in patients with metastatic breast cancer compared to those whose tumors had not yet metastasized.
Further analyses revealed that cells with higher levels of tRNA Arg CCG and tRNA Glu UUC have more ribosomes in mRNAs enriched with these codons, suggesting more active translation on these specific genes. Indeed, they confirmed by mass spectrometry that the levels of the corresponding proteins were increased. Finally, they focused on tRNA Glu UUC and identified two targets, EXOSC2 and GRIPAP1, directly upregulated upon tRNA Glu UUC overexpression. Downregulation of EXOSC2 and GRIPAP1 led to less lung colonization of tRNA overexpressing cells, but not in control cells, indicating that EXOSC2 and GRIPAP1 promote metastasis in the context of tRNA Glu UUC overexpression. To confirm that the upregulation of EXOSC2 was due to codon preference, they mutated every codon on EXOSC2 pairing with tRNA Glu UUC to a non-pairing codon and showed that such mutations decreased protein level. Consistent with these findings in cells, the level of EXOSC2 was higher in invasive breast cancer tissues compared to the noninvasive counterparts in tissue microarrays. To generalize their observations, they correlated the ribosome profiles and tRNA preference scores of all mRNAs to show that transcripts with higher tRNA preference occupied more ribosomes in cells with elevated levels of these tRNAs. Finally, results from their reporter essay supported that increased levels of specific tRNAs enhanced protein production from transcripts enriched with the corresponding codons. Goodarzi et al. (2016) thus clearly demonstrate that tRNA level can affect gene expression landscape in cells, leading to a cancer-specific phenotype. Yet, many questions remain. For instance, how are specific tRNAs (and their precursors) upregulated? Is there a specific transcription factor responsible for such regulation? Is the stability of mature tRNAs also increased? tRNA modifications are known to be important for their stability, and tRNA modifications and their corresponding enzymes are implicated in diseases, including cancer and diabetes. Do they work by modulating tRNA levels, which in turn affects the expression of specific target genes? Moreover, tRNA level can be affected when tRNA processing machinery is not working properly. Recently, it has been shown that a mutation in CLP1, a tRNA maturation enzyme results in neurodegeneration (Karaca et al., 2014; Schaffer et al., 2014) . This raises the question of whether breast cancer is the only context where this mode of regulation applies. Even in the context of breast cancer, are there other tRNAs involved in phenotype modulation through similar mechanisms? tRNAs can produce small RNA fragments (tRFs), and it has been shown that tRFs can affect gene regulation by different mechanisms (Goodarzi et al., 2015; Kumar et al., 2014 Kumar et al., , 2016 . It would be interesting to investigate whether, and if so how, the abundance of tRFs should be integrated into the present findings. Overall, these results encourage us to consider tRNAs more as regulatory elements that actively contribute to dynamic regulation of specific gene expression rather than as factors only controlling protein synthesis efficiency in a global manner. 
